Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559188/
https://www.ncbi.nlm.nih.gov/pubmed/34733355
http://dx.doi.org/10.1177/17562864211049696
_version_ 1784592708439900160
collection PubMed
description
format Online
Article
Text
id pubmed-8559188
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-85591882021-11-02 Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance” Ther Adv Neurol Disord Corrigendum SAGE Publications 2021-10-29 /pmc/articles/PMC8559188/ /pubmed/34733355 http://dx.doi.org/10.1177/17562864211049696 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Corrigendum
Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”
title Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”
title_full Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”
title_fullStr Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”
title_full_unstemmed Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”
title_short Corrigendum to “Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”
title_sort corrigendum to “safety and effectiveness of eculizumab in japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance”
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559188/
https://www.ncbi.nlm.nih.gov/pubmed/34733355
http://dx.doi.org/10.1177/17562864211049696

Ejemplares similares